Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999692 | 0.87 | CYP17A1 (0.46) | TAAR1 | |
| SCHEMBL5034682 | 0.86 | POLB (0.45) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL31190174 | 0.85 | HRH1 (0.46) | LMNAHRH1HTR2ATAAR1 | |
| SCHEMBL6686368 | 0.85 | SIGMAR1 (0.44) | LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL6683678 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL5214468 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL28560209 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL282600 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL6680534 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL11545835 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353167-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-06-24 | — | — | EP | disclosed |
| WO-2017051354-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051353-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| EP-2958889-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | The Scripps Research Institute (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014131023-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-2686342-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012142245-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE GOVERNMENT OF THE UNITED OF AMERIA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2010132869-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7479504-B2 | Edg receptor agonists | MERCK & CO., INC. (US) | 2009-01-20 | — | — | US | disclosed |
| EP-1667982-A4 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-0799200-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | disclosed |
| WO-1997017962-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0059983-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-06-11 | — | — | EP | disclosed |
| US-4578522-A | CHEMICAL INTERMEDIATES FOR BLOOD LIPID CONTROLLING COMPOUNDS | BURROUGHS WELLCOME CO. | 1986-03-25 | — | — | US | disclosed |
| EP-0059983-A1 | Substituted biphenyl compounds for use as a medicament | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-09-15 | — | — | EP | disclosed |